Embecta's corporate headquarters is located in Parsippany, New Jersey, USA.
−Removed: The Company also maintains secondary regional headquarters at leased office facilities in Eysins, Switzerland and Shanghai, China.
+Added: The Company also maintains secondary regional headquarters at leased office facilities in Eysins, Switzerland, Shanghai, China and Singapore.
The Company has a global research and development center in a leased office/lab facility located in Andover, Massachusetts, USA.
−Removed: Embecta has three manufacturing facilities located in Ireland, the United States, and China which occupy an aggregate of approximately 800,000 square feet of floor space.
−Removed: Due to certain regulatory requirements resulting in the delay of the local closing of the Separation in China, BD and its respective subsidiaries have agreed to hold the relevant Embecta assets in China for the use and benefit of Embecta and its respective subsidiaries entitled to such assets in this location and to manage and operate this business on behalf of Embecta in the ordinary course of business in accordance with the past practice of the Diabetes Care Business.
−Removed: Embecta and BD have agreed to defer this local affiliate closing at this location to the time when such regulatory approvals are received.
+Added: Embecta has three manufacturing facilities located in Ireland, the United States, and China which occupy an aggregate of approximately 800,000 square feet of space.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.